Robot-assisted prostatectomy for PT3. Oncological and functional outcomes


DOI: https://dx.doi.org/10.18565/urology.2023.6.133-137

Medvedev R.M., Kolontarev K.B., Govorov A.V., Skrupskiy K.S., Vasilyev A.O., Dyakov V.V., Kotelnikova A.A., Vitoslavskii A.A., Pushkar D.Yu.

1) Department of Urology of Scientific and Educational Institute of the Clinical Medicine named after N.A. Semashko FGBOU VO “Russian University of Medicine”, Moscow, Russia; 2) Moscow Urological Center of S.P. Botkin City Clinical Hospital, Moscow, Russia
In 2020, prostate cancer (PCa) ranked third in the structure of the most significant oncological diseases. In the Russian Federation, in terms of the frequency of detection among men, prostate cancer is second only to tumors of the upper respiratory tract and lungs, accounting for 14.9%. Radical prostatectomy (RP) in various modifications is still the most common treatment for localized prostate cancer, despite the existence of alternatives such as active surveillance, hormonal and radiation therapy, cryoablation, and others. And the technological pinnacle of the surgical treatment of prostate cancer at the moment is robot-assisted prostatectomy, the widespread use of which was marked by the publication of J. Binder back in 2002. This technology combined the advantages of minimally invasive laparoscopic RP with improved surgeon ergonomics and technical ease of vesicourethral anastomosis reconstruction and has now become the preferred minimally invasive approach. This article will consider the use of a robot-assisted technique in the stage of T3 prostate cancer.

About the Autors


Corresponding author: K.B. Kolontarev – Ph.D., MD, Professor at the Department of Urology of Scientific and Educational Institute of the Clinical Medicine named after N.A. Semashko FGBOU VO “Russian University of Medicine”, Deputy Chief of the Moscow Urological Center of S.P. Botkin City Clinical Hospital, Moscow, Russia; e-mail: kb80@yandex.ru


Similar Articles


Бионика Медиа